

# Review of the Comparative Pharmacology and Clinical

Journal of Clinical Oncology

17, 409-409

DOI: 10.1200/jco.1999.17.1.409

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current Strategies for Prevention, Detection, and Treatment of Ovarian Cancer. <i>Journal of the American Pharmacists Association</i> , 2000, 40, 392-401.	0.6	11
2	Antiproliferative activity in vitro of new malatoplatinum(II) complexes. <i>Anti-Cancer Drugs</i> , 2000, 11, 363-368.	0.7	10
3	The clinical pharmacology of alkylating agents in high-dose chemotherapy. <i>Anti-Cancer Drugs</i> , 2000, 11, 515-533.	0.7	40
4	Optimum chemotherapy for ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2000, 10, 33-37.	1.2	132
5	Effect of cisplatin on mitochondrial protein, glutathione, and succinate dehydrogenase in Dalton lymphoma-bearing mice. <i>Cell Biology and Toxicology</i> , 2000, 16, 363-373.	2.4	31
6	Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2000, 83, 858-862.	2.9	43
7	Phase I/II trial of docetaxel and carboplatin in previously untreated patients with advanced non-small-cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2000, 5, 323-327.	1.0	0
8	Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma. <i>Annals of Oncology</i> , 2000, 11, 201-206.	0.6	22
9	Prospective Validation of Renal Function-Based Carboplatin Dosing in Children With Cancer: A United Kingdom Children's Cancer Study Group Trial. <i>Journal of Clinical Oncology</i> , 2000, 18, 3614-3621.	0.8	60
10	Novel combination chemotherapy in the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 1131-1161.	0.9	18
11	Comparison of In Vitro Growth-inhibitory Activity of Carboplatin and Cisplatin on Leukemic Cells and Hematopoietic Progenitors: the Myelosuppressive Activity of Carboplatin May Be Greater Than Its Antileukemic Effect. <i>Japanese Journal of Clinical Oncology</i> , 2000, 30, 562-567.	0.6	34
12	A Genome-Wide Screening in <i>Saccharomyces cerevisiae</i> for Genes That Confer Resistance to the Anticancer Agent Cisplatin. <i>Biochemical and Biophysical Research Communications</i> , 2000, 269, 767-774.	1.0	37
13	Hyperthermic isolated regional perfusion of the limb with carboplatin. <i>European Journal of Surgical Oncology</i> , 2000, 26, 792-797.	0.5	20
14	Docetaxel. <i>Drugs and Aging</i> , 2000, 17, 53-80.	1.3	23
15	New Developments and Approaches in the Platinum Arena. <i>Drugs</i> , 2000, 59, 29-36.	4.9	98
16	Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma. <i>Lung Cancer</i> , 2001, 32, 189-196.	0.9	10
17	Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide. <i>Lung Cancer</i> , 2001, 33, 241-248.	0.9	7
18	Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study. <i>Lung Cancer</i> , 2001, 34, 1-13.	0.9	36

#	ARTICLE	IF	CITATIONS
19	The (ir)relevance of plasma protein binding of anticancer drugs. <i>Netherlands Journal of Medicine</i> , 2001, 59, 196-207.	0.6	34
20	Modification of the sensitivity to cisplatin with c-myc over-expression or down-regulation in colon cancer cells. <i>Anti-Cancer Drugs</i> , 2001, 12, 829-834.	0.7	14
21	Gemcitabine plus etoposide in chemo-naïve extensive disease small-cell lung cancer: A multi-centre phase II study. <i>Annals of Oncology</i> , 2001, 12, 835-840.	0.6	17
22	Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. <i>Annals of Oncology</i> , 2001, 12, 1195-1203.	0.6	115
23	Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. <i>Blood</i> , 2001, 97, 638-644.	0.6	45
24	Carboplatin AUC8 in combination with etoposide and bleomycin in the treatment of intermediate and poor-risk metastatic germ cell tumours: a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 370-372.	1.1	4
25	Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 141-144.	1.1	51
26	Carboplatin and doxorubicin (CARDOX) for nonmetastatic hepatoblastoma: A discouraging pilot study. <i>Medical and Pediatric Oncology</i> , 2001, 36, 332-334.	1.0	5
27	Synthesis, Conformational Studies, and Investigations on the Estrogen Receptor Binding of [R/S-1-(2,6-Dichloro-4-hydroxyphenyl)-ethylenediamine]platinum(II) Complexes. <i>Archiv Der Pharmazie</i> , 2001, 334, 93-100.	2.1	4
28	Quality of Life in Ovarian Cancer Patients Receiving Chemotherapy. <i>Gynecologic Oncology</i> , 2001, 81, 490-495.	0.6	77
29	Superselective intra-arterial carboplatin for treatment of intracranial neoplasms: experience in 100 procedures. <i>Journal of Neuro-Oncology</i> , 2001, 51, 151-158.	1.4	30
30	Hematotoxicity and blood glutathione levels after cisplatin treatment of tumor-bearing mice. <i>Cell Biology and Toxicology</i> , 2001, 17, 357-370.	2.4	25
31	Gemcitabine/Carboplatin in Advanced Urothelial Cancer. <i>Seminars in Oncology</i> , 2001, 28, 19-24.	0.8	14
32	Irinotecan: Future Directions in Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2001, 2, S9-S13.	1.1	3
33	Neoadjuvant chemotherapy in early-stage non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 229-235.	1.1	0
34	What Is the "Best" Platinum: Cisplatin, Carboplatin, or Oxaliplatin?. <i>Cancer Investigation</i> , 2001, 19, 756-760.	0.6	46
35	Modulation of Cisplatin Cytotoxicity and Cisplatin-Induced DNA Cross-Links in HepG2 Cells by Regulation of Glutathione-Related Mechanisms. <i>Molecular Pharmacology</i> , 2001, 59, 837-843.	1.0	79
36	Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). <i>Journal of the American Veterinary Medical Association</i> , 2001, 218, 1444-1448.	0.2	123

#	ARTICLE	IF	CITATIONS
37	Is cisplatin still the best platinum compound in non-small-cell lung cancer?. <i>Annals of Oncology</i> , 2002, 13, 1515-1517.	0.6	19
38	Platinum drugs in the treatment of non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2002, 87, 825-833.	2.9	92
39	Small Cell Lung Cancer: Defining a Role for Emerging Platinum Drugs. <i>Oncology</i> , 2002, 63, 105-114.	0.9	27
40	Toxicity of High-Dose Carboplatin: Ultrafiltered and Not Total Plasma Pharmacokinetics Is of Clinical Relevance. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 762-773.	1.0	14
41	High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2002, 20, 4209-4216.	0.8	171
42	Pharmacokinetics in Cancer Treatment. <i>American Journal of Cancer</i> , 2002, 1, 33-53.	0.4	1
43	Modulation of cisplatin pharmacodynamics by Cremophor EL. <i>European Journal of Cancer</i> , 2002, 38, 205-213.	1.3	13
44	Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer. <i>European Journal of Cancer</i> , 2002, 38, 1194-1200.	1.3	14
45	BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. <i>European Journal of Cancer</i> , 2002, 38, 1148-1156.	1.3	36
46	Carboplatin in Elderly Patients. <i>Tumori</i> , 2002, 88, S35-S36.	0.6	0
47	Platinum agents in the treatment of osteosarcoma: Efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines. <i>Medical and Pediatric Oncology</i> , 2002, 39, 573-580.	1.0	35
48	Calpain Immunoreactivity and Morphological Damage in Chinchilla Inner Ears after Carboplatin. <i>JARO - Journal of the Association for Research in Otolaryngology</i> , 2002, 3, 68-79.	0.9	27
49	Particular aspects of platinum compounds used at present in cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 42, 317-325.	2.0	322
50	Association between in Vitro Platinum Resistance in the EDR Assay and Clinical Outcomes for Ovarian Cancer Patients. <i>Gynecologic Oncology</i> , 2002, 87, 8-16.	0.6	89
51	A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. <i>Investigational New Drugs</i> , 2002, 20, 343-349.	1.2	40
52	Changes in glutathione-related enzymes in tumor-bearing mice after cisplatin treatment. <i>Cell Biology and Toxicology</i> , 2002, 18, 349-358.	2.4	25
53	Tumour-inhibiting platinum complexes—state of the art and future perspectives. , 2003, 146, 1-53.		355
54	Concurrent carboplatin with pelvic radiation therapy in the primary treatment of cervix cancer. <i>Gynecologic Oncology</i> , 2003, 89, 499-503.	0.6	38

#	ARTICLE	IF	CITATIONS
55	Cisplatin-induced genotoxic effects and endogenous glutathione levels in mice bearing ascites Dalton's lymphoma. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2003, 526, 9-18.	0.4	23
56	A PHASE I study of carboplatin concurrent with radiation in FIGO stage IIIB cervix uteri carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 1361-1365.	0.4	29
57	Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer. <i>British Journal of Cancer</i> , 2003, 89, 787-794.	2.9	13
58	cis-[Pt(NH <sub>3</sub> ) <sub>2</sub> (L)] <sub>2</sub> +/(L = Cl, H <sub>2</sub> O, NH <sub>3</sub> ) Binding to Purines and CO: Does "Back-Donation" Play a Role?. <i>Inorganic Chemistry</i> , 2003, 42, 8615-8617.	1.9	16
59	Carboplatin and Doxorubicin Combination Chemotherapy for the Treatment of Appendicular Osteosarcoma in the Dog. <i>Journal of Veterinary Internal Medicine</i> , 2003, 17, 199-205.	0.6	69
61	Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2003, 21, 3194-3200.	0.8	1,878
62	Neoadjuvant chemotherapy and chemoradiotherapy for non-small cell lung cancer: current status and future prospects. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 843-852.	0.9	1
63	Cytostatic drugs. <i>Side Effects of Drugs Annual</i> , 2003, 26, 490-511.	0.6	2
64	Changes in endogenous tissue glutathione level in relation to murine ascites tumor growth and the anticancer activity of cisplatin. <i>Brazilian Journal of Medical and Biological Research</i> , 2003, 36, 53-63.	0.7	33
65	Utility of Antioncogene Ribozymes and Antisense Oligonucleotides in Reversing Drug Resistance. , 2005, 106, 215-234.		2
66	The Synergistic Cytotoxicity of Cisplatin and Taxol in Killing Oral Squamous Cell Carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 499-504.	0.6	21
67	Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. <i>Annals of Oncology</i> , 2004, 15, 51-54.	0.6	42
68	Platinum Complex Cytotoxicity Tested by the Electrical Resistance Breakdown Assay. <i>Cellular Physiology and Biochemistry</i> , 2004, 14, 425-430.	1.1	6
69	Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 3852-3859.	0.8	373
71	A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131. <i>Annals of Oncology</i> , 2004, 15, 1115-1122.	0.6	17
72	Carboplatin in Combination Therapy for Metastatic Breast Cancer. <i>Oncologist</i> , 2004, 9, 518-527.	1.9	62
73	Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. <i>Kidney International</i> , 2004, 66, 196-202.	2.6	147
74	Carboplatin pharmacokinetics following a single-dose infusion in sulphur-crested cockatoos ( <i>Cacatua galerita</i> ). <i>Australian Veterinary Journal</i> , 2004, 82, 366-369.	0.5	16

#	ARTICLE	IF	CITATIONS
75	Population pharmacokinetics of cisplatin in adult cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 105-112.	1.1	40
76	Low urine osmolarity as a determinant of cisplatin-induced nephrotoxicity. <i>International Journal of Cancer</i> , 2004, 111, 131-137.	2.3	31
77	Synthesis, antimicrobial activity and chemotherapeutic potential of inorganic derivatives of 2-(4-thiazolyl)benzimidazole{thiabendazole}: X-ray crystal structures of [Cu(TBZH) <sub>2</sub> Cl]Cl·H <sub>2</sub> O·EtOH and TBZH <sub>2</sub> NO <sub>3</sub> (TBZH=thiabendazole). <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 1023-1031.	1.5	80
78	Kinetic Study on the Reactions of Platinum Drugs with Glutathione. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 658-666.	1.3	64
79	Interaction of Oxaliplatin, Cisplatin, and Carboplatin with Hemoglobin and the Resulting Release of a Heme Group. <i>Chemical Research in Toxicology</i> , 2004, 17, 1391-1397.	1.7	98
80	Current research in avian chemotherapy. <i>Veterinary Clinics of North America - Exotic Animal Practice</i> , 2004, 7, 821-831.	0.4	6
82	Status and trends of chemotherapy for advanced NSCLC. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 26-33.	2.2	2
83	Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2004, 43, 203-208.	0.9	12
84	Clinical Issues in the Management of Non-Small-Cell Lung Cancer and the Role of Platinum-Based Therapy. <i>Clinical Lung Cancer</i> , 2004, 5, 274-289.	1.1	15
85	Tumor control in birds. <i>Journal of Exotic Pet Medicine</i> , 2004, 13, 25-43.	0.5	51
86	Platinum-based chemotherapy in metastatic breast cancer: current status. <i>Cancer Treatment Reviews</i> , 2004, 30, 53-81.	3.4	184
87	Chemotherapy in a Patient with Small-cell Lung Cancer Undergoing Haemodialysis. <i>Clinical Oncology</i> , 2005, 17, 663.	0.6	8
88	Phase II Trial of Weekly Paclitaxel and Carboplatin Chemotherapy in Patients with Advanced Transitional Cell Cancer. <i>European Urology</i> , 2005, 48, 246-251.	0.9	6
89	Pharmacological inhibitors of extracellular signal-regulated protein kinases attenuate the apoptotic action of cisplatin in human myeloid leukemia cells via glutathione-independent reduction in intracellular drug accumulation. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2005, 1743, 269-279.	1.9	28
90	Role of O <sup>6</sup> -methylguanine-DNA methyltransferase and effect of O <sup>6</sup> -benzylguanine on the anti-tumor activity of cis-diaminedichloroplatinum(II) in oral cancer cell lines. <i>Oral Oncology</i> , 2005, 41, 984-993.	0.8	14
91	Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer. <i>BMC Cancer</i> , 2005, 5, 10.	1.1	6
92	Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. <i>Gynecologic Oncology</i> , 2005, 96, 168-172.	0.6	36
93	A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). <i>Gynecologic Oncology</i> , 2005, 96, 444-451.	0.6	24

#	ARTICLE	IF	CITATIONS
94	Principles of Chemotherapy for Genitourinary Cancer. , 2005, , 51-87.		0
95	Treatment of Advanced Non-Small Cell Lung Cancer in the Elderly. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 289-297.	0.8	7
96	Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 3417-3424.	3.2	40
97	Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Does Cisplatin Versus Carboplatin Make a Difference?. Journal of Clinical Oncology, 2005, 23, 6276-6277.	0.8	5
98	Carboplatin Administration in Sulphur-crested Cockatoos (Cacatua galerita): Clinical Observations. , 2005, 19, 92-97.		7
99	New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opinion on Investigational Drugs, 2005, 14, 1033-1046.	1.9	42
100	Interactions Between Antiretrovirals and Antineoplastic Drug Therapy. Clinical Pharmacokinetics, 2005, 44, 111-145.	1.6	91
101	Herb-Drug Interactions. Drugs, 2005, 65, 1239-1282.	4.9	520
102	Principles of Chemotherapy. , 2006, , 14-40.		1
103	Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer. Lung Cancer, 2006, 54, 379-385.	0.9	4
104	Synthesis, Superoxide Dismutase Mimetic and Anticancer Activities of Metal Complexes of 2,2-Dimethylpentanedioic Acid(2dmepdaH <sub>2</sub> ) and 3,3-Dimethylpentanedioic acid(3dmepdaH <sub>2</sub> ): X-Ray Crystal Structures of [Cu(3dmepda)(bipy)] <sub>2</sub> ·6H <sub>2</sub> O and [Cu(2dmepda)(bipy)(EtOH)] <sub>2</sub> ·4EtOH(bipy=2,2'-Bipyridine). Bioinorganic Chemistry and Applications, 2006, 2006, 1-11.	1.8	22
106	Phase II Trial of Gemcitabine-Carboplatin-Paclitaxel as Neoadjuvant Chemotherapy for Operable Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 135-140.	0.5	8
107	The role of platinum-based therapy for HER-2-positive breast cancer. Breast Cancer Online: BCO, 2006, 9, 1-7.	0.1	1
108	The Role of Chemotherapy in the Treatment of Malignant Astrocytomas. Canadian Journal of Neurological Sciences, 2006, 33, 127-140.	0.3	14
109	Phase II Trial of Gemcitabine-Carboplatin-Paclitaxel as Neoadjuvant Chemotherapy for Operable Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 135-140.	0.5	10
111	Carboplatin for treatment of a Sertoli cell tumor in a mallard (Anas platyrhynchos). Veterinary and Comparative Oncology, 2006, 4, 51-56.	0.8	13
112	Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer. British Journal of Cancer, 2006, 94, 1267-1271.	2.9	21
113	The development of platinum compounds and their possible combination. Critical Reviews in Oncology/Hematology, 2006, 60, 59-75.	2.0	94

#	ARTICLE	IF	CITATIONS
114	Deoxyribonucleic acid (DNA) biosensors for environmental risk assessment and drug studies. <i>Analytica Chimica Acta</i> , 2006, 573-574, 81-89.	2.6	114
115	Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 837, 29-34.	1.2	39
116	New Imidazole-Coordinated Chemotherapeutics With Low Epithelial Toxicity. <i>Cell Biochemistry and Biophysics</i> , 2006, 45, 31-42.	0.9	1
117	Paclitaxel-Carboplatin Combination Chemotherapy in Advanced Breast Cancer: Accumulating Evidence for Synergy, Efficacy, and Safety. <i>Medical Oncology</i> , 2006, 23, 147-160.	1.2	26
118	A phase I and pharmacokinetic study of iriflufen and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2006, 24, 311-319.	1.2	14
119	A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2006, 78, 311-316.	1.4	41
120	Phase I/II Trial of Docetaxel and Carboplatin as a First-Line Therapy in Patients with Stage IV Non-Small-Cell Lung Cancer. <i>Lung</i> , 2006, 184, 133-139.	1.4	5
121	Analysis of cytotoxicities of platinum compounds. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 257-267.	1.1	81
122	A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341), Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 207-215.	1.1	41
123	Feasibility study comparing docetaxel+ cisplatin versus docetaxel+ carboplatin as first-line chemotherapy for ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 101, 495-498.	0.6	10
124	Non-small-cell lung cancer: which platinum for gemcitabine?. <i>Annals of Oncology</i> , 2006, 17, v79-v81.	0.6	0
125	Treatment of advanced non-small cell lung cancer: chemotherapy with or without cisplatin?. <i>Annals of Oncology</i> , 2006, 17, ii83-ii87.	0.6	8
126	Platinum-containing cytostatic drugs. , 2006, , 2849-2872.		0
127	End-Stage Renal Disease Following Carboplatin Chemotherapy for a Nasopharyngeal Carcinoma. <i>Renal Failure</i> , 2007, 29, 1049-1051.	0.8	3
128	Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer. <i>Oncology</i> , 2007, 73, 407-414.	0.9	26
129	Bioinorganic Chemistry: The Study of the Fate of Platinum-Based Antitumour Drugs. <i>Current Chemical Biology</i> , 2007, 1, 278-289.	0.2	6
130	Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 3265-3275.	0.9	11
131	Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2007, 99, 847-857.	3.0	574



#	ARTICLE	IF	CITATIONS
132	Enhanced Survival and Cure of F98 Glioma-bearing Rats following Intracerebral Delivery of Carboplatin in Combination with Photon Irradiation. <i>Clinical Cancer Research</i> , 2007, 13, 5195-5201.	3.2	65
133	G1 arrest induction represents a critical determinant for cisplatin cytotoxicity in G1 checkpoint-retaining human cancers. <i>Anti-Cancer Drugs</i> , 2007, 18, 411-417.	0.7	22
134	Chemotherapy and Delivery in the Treatment of Primary Brain Tumors. <i>Current Clinical Pharmacology</i> , 2007, 2, 197-211.	0.2	9
135	Management of solid tumours in organ-transplant recipients. <i>Lancet Oncology</i> , The, 2007, 8, 921-932.	5.1	95
136	Bifunctional Binding of Cisplatin to DNA: Why Does Cisplatin Form 1,2-Intrastrand Cross-Links with AG But Not with GA?. <i>Journal of the American Chemical Society</i> , 2007, 129, 5023-5030.	6.6	88
137	Maternal-fetal transport kinetics of carboplatin in the perfused human placental lobule: In vitro study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2007, 20, 695-701.	0.7	9
138	A Systematic Review of Limited Sampling Strategies for Platinum Agents Used in Cancer Chemotherapy. <i>Clinical Pharmacokinetics</i> , 2007, 46, 471-494.	1.6	17
139	Long-Standing Debate on Cisplatin- Versus Carboplatin-Based Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 96.	0.5	35
140	Short Hydration Regimen and Nephrotoxicity of Intermediate to High-Dose Cisplatin-Based Chemotherapy for Outpatient Treatment in Lung Cancer and Mesothelioma. <i>Tumori</i> , 2007, 93, 138-144.	0.6	65
141	A Suggestion of Electrochemical Biosensor for Study of Platinum(II)-DNA Interactions. <i>Electroanalysis</i> , 2007, 19, 331-338.	1.5	57
142	Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. <i>Cancer</i> , 2007, 109, 939-948.	2.0	44
143	Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors. <i>Cancer</i> , 2007, 109, 1413-1419.	2.0	12
144	Synthesis, catalase, superoxide dismutase and antitumour activities of copper(II) carboxylate complexes incorporating benzimidazole, 1,10-phenanthroline and bipyridine ligands: X-ray crystal structures of [Cu(BZA)2(bipy)(H2O)], [Cu(SalH)2(BZDH)2] and [Cu(CH3COO)2(5,6-DMBZDH)2] (SalH2=salicylic acid; BZAH=benzoic acid; BZDH=benzimidazole and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 247 Td (5,6-DMBZDH=5,6-di	1.0	129
145	Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. <i>British Journal of Cancer</i> , 2007, 97, 162-169.	2.9	185
146	Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity. <i>Cancer Science</i> , 2007, 98, 1408-1412.	1.7	15
147	Human renal UOK130 tumor cells: A drug resistant cell line with highly selective over-expression of glutathione S-transferase- $\kappa$ isozyme. <i>European Journal of Pharmacology</i> , 2007, 568, 61-67.	1.7	12
149	Concurrent carboplatin and paclitaxel with pelvic radiation therapy in the primary treatment of cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 205.e1-205.e7.	0.7	6
150	Irinotecan-cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 91-102.	1.1	12

#	ARTICLE	IF	CITATIONS
151	Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review. <i>Oncology Reviews</i> , 2007, 1, 162-169.	0.8	2
152	Pharmacodynamic model for chemotherapy-induced anemia in rats. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 123-133.	1.1	41
153	Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 841-847.	1.1	18
154	Investigation of interaction between human hemoglobin A <sub>0</sub> and platinum anticancer drugs by capillary isoelectric focusing with whole column imaging detection. <i>Journal of Separation Science</i> , 2008, 31, 1803-1809.	1.3	14
155	Concurrent Weekly Cisplatin Chemotherapy and Radiotherapy in a Haemodialysis Patient with Locally Advanced Cervix Cancer. <i>Clinical Oncology</i> , 2008, 20, 6-11.	0.6	15
156	Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials. <i>Lung Cancer</i> , 2008, 59, 1-11.	0.9	199
157	Bioactive fragments synergically involved in the design of new generation Pt(ii) and Pd(ii)-based anticancer compounds. <i>Dalton Transactions</i> , 2008, , 5897.	1.6	21
158	Small Cell Lung Cancer. <i>Mayo Clinic Proceedings</i> , 2008, 83, 355-367.	1.4	412
159	Chemotherapeutic agents and the skin: An update. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 545-570.	0.6	231
160	Phase II study of hepatic arterial infusion of a fine powder formulation of cisplatin for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2008, 38, 474-483.	1.8	105
161	Squalene Selectively Protects Mouse Bone Marrow Progenitors Against Cisplatin and Carboplatin-Induced Cytotoxicity In Vivo Without Protecting Tumor Growth. <i>Neoplasia</i> , 2008, 10, 1105-IN4.	2.3	72
163	Multidisciplinary Management of Locally Advanced SCCHN: Optimizing Treatment Outcomes. <i>Oncologist</i> , 2008, 13, 899-910.	1.9	55
164	The Renaissance of Platinum-Based Chemotherapy for Metastatic Breast Cancer. <i>Journal of Chemotherapy</i> , 2008, 20, 551-560.	0.7	5
165	Clinical pharmacology of cancer therapies in older adults. <i>British Journal of Cancer</i> , 2008, 98, 517-522.	2.9	79
166	Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 1464-1469.	3.2	39
167	Interaction of Cisplatin with the Human Organic Cation Transporter 2. <i>Clinical Cancer Research</i> , 2008, 14, 3875-3880.	3.2	142
170	Imaging the distribution of individual platinum-based anticancer drug molecules attached to single-wall carbon nanotubes. <i>Nanomedicine</i> , 2009, 4, 763-772.	1.7	24
171	Phase II Trial of Weekly Gemcitabine and Split-dose Cisplatin for Advanced Non-small-cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 779-783.	0.6	5

#	ARTICLE	IF	CITATIONS
172	Whatâ€™s positive about â€˜triple-negativeâ€™ breast cancer?. <i>Future Oncology</i> , 2009, 5, 1015-1025.	1.1	22
173	Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 4475-4483.	3.2	0
174	Chemotherapy with Cisplatin and Vincristine for Optic Pathway/Hypothalamic Astrocytoma in Young Children. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 277-283.	0.6	17
175	Current State-of-the-Art for Concurrent Chemoradiation. <i>Seminars in Radiation Oncology</i> , 2009, 19, 3-10.	1.0	49
176	Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. <i>Biochemical Pharmacology</i> , 2009, 78, 1263-1271.	2.0	79
177	Polymeric drug delivery of platinum-based anticancer agents. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2299-2316.	1.6	114
178	A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1303-1314.	1.2	57
179	Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase. <i>Cell Biology and Toxicology</i> , 2009, 25, 217-225.	2.4	43
180	Investigation on pharmacokinetics, tissue distribution and excretion of a novel anticancer platinum compound by inductively coupled plasma mass spectrometry after intravenous administration to rats. <i>Archives of Pharmacal Research</i> , 2009, 32, 1621-1628.	2.7	9
181	Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 396-402.	2.3	338
182	Randomized phase II trial of gemcitabine and either day 1 or day 8 carboplatin for advanced nonâ€‘smallâ€‘cell lung cancer: Is thrombocytopenia predictable?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009, 5, 24-31.	0.7	0
183	Human serum albumin interaction with oxaliplatin studied by capillary isoelectric focusing with the whole column imaging detection and spectroscopic method. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009, 50, 570-575.	1.4	34
184	Biological activity of metal ions complexes of chromones, coumarins and flavones. <i>Coordination Chemistry Reviews</i> , 2009, 253, 2588-2598.	9.5	251
185	Targeted Killing of Cancer Cells <i>in Vivo</i> and <i>in Vitro</i> with EGF-Directed Carbon Nanotube-Based Drug Delivery. <i>ACS Nano</i> , 2009, 3, 307-316.	7.3	796
187	Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin. <i>Hepatology Research</i> , 2009, 39, 346-354.	1.8	23
188	A Phase I Study of Amrubicin and Carboplatin for Previously Untreated Patients with Extensive-Disease Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 741-745.	0.5	13
189	A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. <i>Anti-Cancer Drugs</i> , 2010, 21, 777-784.	0.7	17
190	Successful Chemotherapy for Small-Cell Lung Cancer in an Elderly Patient Undergoing Continuous Ambulatory Peritoneal Dialysis. <i>Internal Medicine</i> , 2010, 49, 1179-1183.	0.3	5

#	ARTICLE	IF	CITATIONS
191	Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 941-951.	1.1	19
192	Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 813-817.	1.1	25
193	Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes. <i>Investigational New Drugs</i> , 2010, 28, 859-865.	1.2	16
194	Akt inhibitor enhances apoptotic effect of carboplatin on human epithelial ovarian carcinoma cell lines. <i>European Journal of Pharmacology</i> , 2010, 632, 7-13.	1.7	9
195	Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: A phase II study based on surgical reassessment. <i>Gynecologic Oncology</i> , 2010, 119, 451-456.	0.6	55
196	Comparison of two methods for carboplatin dosing in children with retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2010, 55, 47-54.	0.8	18
197	Differential transport of platinum compounds by the human organic cation transporter hOCT2 (<i>hSLC22A2</i>). <i>British Journal of Pharmacology</i> , 2010, 159, 898-908.	2.7	108
198	Cilastatin Attenuates Cisplatin-Induced Proximal Tubular Cell Damage. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 334, 419-429.	1.3	71
199	Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer. <i>Annals of Oncology</i> , 2010, 21, 961-967.	0.6	81
200	Efficacy and Safety of Modified Rituximab-ESHAP Therapy for Relapsed/Refractory B-Cell Lymphoma. <i>Journal of Chemotherapy</i> , 2010, 22, 54-57.	0.7	12
201	The Role of Chemotherapy in the Management of Patients with Head and Neck Cancer. <i>Seminars in Plastic Surgery</i> , 2010, 24, 137-147.	0.8	6
202	An Adsorptive Transfer Technique Coupled with Brdicka Reaction to Reveal the Importance of Metallothionein in Chemotherapy with Platinum Based Cytostatics. <i>International Journal of Molecular Sciences</i> , 2010, 11, 4826-4842.	1.8	20
203	Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. <i>Toxicology Letters</i> , 2010, 192, 108-114.	0.4	49
204	Synthesis and Biological Activities of Transition Metal Complexes Based on Acetylsalicylic Acid as Neo-Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 6889-6898.	2.9	50
205	Effect of glutathione combined with cisplatin and oxaliplatin on the proliferation and apoptosis of lung carcinoma cell line. <i>Toxicology Mechanisms and Methods</i> , 2010, 20, 487-492.	1.3	10
206	Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 12435-12440.	3.3	121
207	Structural and biochemical changes in mitochondria after cisplatin treatment of Daltonâ€™s lymphoma-bearing mice. <i>Mitochondrion</i> , 2010, 10, 38-45.	1.6	19
208	Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. <i>European Journal of Cancer</i> , 2010, 46, 3016-3021.	1.3	74

#	ARTICLE	IF	CITATIONS
209	Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2010, 394, 600-605.	1.0	126
210	Phase I/II study of a fine powder formulation of cisplatin for transcatheter arterial chemoembolization in hepatocellular carcinoma. <i>Hepatology Research</i> , 2010, 40, 369-375.	1.8	10
211	Impact of Age, Sex, and Comorbidity on Cancer Therapy and Disease Progression. <i>Journal of Clinical Oncology</i> , 2010, 28, 4086-4093.	0.8	212
212	Effect of Thioethers on DNA Platination by trans-Platinum Complexes. <i>Inorganic Chemistry</i> , 2011, 50, 8168-8176.	1.9	17
213	Honokiol: a promising small molecular weight natural agent for the growth inhibition of oral squamous cell carcinoma cells. <i>International Journal of Oral Science</i> , 2011, 3, 34-42.	3.6	43
214	Systemic Therapies for Metastatic Renal Cell Carcinoma in Older Adults. <i>Drugs and Aging</i> , 2011, 28, 635-649.	1.3	16
215	Development of highly effective three-component cytoprotective adjuncts for cisplatin cancer treatment: synthesis and in vivo evaluation in S180-bearing mice. <i>Metallomics</i> , 2011, 3, 1212.	1.0	2
216	Drug transporters of platinum-based anticancer agents and their clinical significance. <i>Drug Resistance Updates</i> , 2011, 14, 22-34.	6.5	191
217	Hepatic Arterial Infusion Therapy with a Fine Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 69-75.	0.6	30
218	A retrospective comparative study of epirubicin lipiodol emulsion and cisplatin lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , 2011, 22, 277-282.	0.7	34
219	Carboplatin-Induced Hematuria in a Patient of Breast Carcinoma. A Case Report. <i>American Journal of Therapeutics</i> , 2011, 18, e269-e270.	0.5	3
221	Innovator and generic cisplatin formulations: Comparison of renal toxicity. <i>Cancer Science</i> , 2011, 102, 162-165.	1.7	30
222	Which therapy works better in choroid plexus carcinomas?. <i>Journal of Neuro-Oncology</i> , 2011, 103, 155-162.	1.4	19
223	Effects of Cisplatin on Lymphocyte Structure and Functions in Mice with Ehrlich Ascitic Carcinoma. <i>Bulletin of Experimental Biology and Medicine</i> , 2011, 151, 62-65.	0.3	3
224	Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1455-1461.	1.1	24
225	Cytotoxic effect of a polymer-copper(II) complex containing 2,2'-bipyridyl ligand on human lung cancer cells. <i>Medicinal Chemistry Research</i> , 2011, 20, 726-731.	1.1	15
226	A DFT study of a novel oxime anticancer <i>trans</i> platinum complex: Monofunctional and bifunctional binding to purine bases. <i>International Journal of Quantum Chemistry</i> , 2011, 111, 1907-1920.	1.0	11
227	Prevention of intrahepatic distant recurrence by transcatheter arterial infusion chemotherapy with platinum agents for stage I/II hepatocellular carcinoma. <i>Cancer</i> , 2011, 117, 4018-4025.	2.0	20

#	ARTICLE	IF	CITATIONS
228	Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996–2006). <i>Journal of the American Veterinary Medical Association</i> , 2011, 238, 195-206.	0.2	61
229	Preclinical and Clinical Evaluation of Intraductally Administered Agents in Early Breast Cancer. <i>Science Translational Medicine</i> , 2011, 3, 106ra108.	5.8	66
230	Neurotoxicity Caused by the Treatment with Platinum Analogues. <i>Chemotherapy Research and Practice</i> , 2011, 2011, 1-5.	1.6	100
231	Proteomic Approaches in Understanding a Detected Relationship between Chemotherapy-Induced Nephrotoxicity and Cell Respiration in HK-2 Cells. <i>Nephron Physiology</i> , 2011, 119, p1-p10.	1.5	12
232	Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy. <i>Nanotechnology</i> , 2011, 22, 265101.	1.3	27
233	Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). <i>Annals of Oncology</i> , 2011, 22, 636-642.	0.6	50
234	Rap1-GTP-interacting Adaptor Molecule (RIAM) Protein Controls Invasion and Growth of Melanoma Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 18492-18504.	1.6	35
235	Impact of a new assay for measuring serum creatinine levels on carboplatin dosing. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 1136-1141.	0.5	10
236	Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in Japan. <i>Cancers</i> , 2012, 4, 165-183.	1.7	26
237	Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data. <i>Journal of Clinical Oncology</i> , 2012, 30, 1692-1698.	0.8	422
238	Platinum-Induced Ototoxicity in Children: A Consensus Review on Mechanisms, Predisposition, and Protection, Including a New International Society of Pediatric Oncology Boston Ototoxicity Scale. <i>Journal of Clinical Oncology</i> , 2012, 30, 2408-2417.	0.8	298
239	Impact of Long-Term Serum Platinum Concentrations on Neuro- and Ototoxicity in Cisplatin-Treated Survivors of Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 300-307.	0.8	155
240	Preparation and In Vivo Evaluation of Dichloro(1,2-Diaminocyclohexane)platinum(II)-Loaded Core Cross-Linked Polymer Micelles. <i>Chemotherapy Research and Practice</i> , 2012, 2012, 1-10.	1.6	12
241	Pegylated liposomal doxorubicin plus carboplatin in patients with metastatic breast cancer: a phase II study. <i>Annals of Oncology</i> , 2012, 23, 2599-2605.	0.6	8
242	Optical molecular imaging approach for rapid assessment of response of individual cancer cells to chemotherapy. <i>Journal of Biomedical Optics</i> , 2012, 17, 1060061.	1.4	7
244	From Amino Acids to Proteins as Targets for Metal-based Drugs. <i>Current Drug Metabolism</i> , 2012, 13, 306-320.	0.7	23
245	Downregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirus. <i>Oncology Reports</i> , 2012, 27, 971-978.	1.2	7
246	Evaluation of the effect of glutathione on cisplatin antitumor activity and kidney injury at different administration times. <i>Molecular Medicine Reports</i> , 2012, 6, 1075-1080.	1.1	8

#	ARTICLE	IF	CITATIONS
247	Small-cell lung cancer: state-of-the-art treatment. Lung Cancer Management, 2012, 1, 47-54.	1.5	0
248	Carboplatin treatment of antiestrogen-resistant breast cancer cells. International Journal of Oncology, 2012, 41, 1863-1870.	1.4	6
249	Chemioterapia e terapie mirate nel trattamento delle neoplasie delle vie aerodigestive superiori (escluso il linfoma maligno). EMC - Otorinolaringoiatria, 2012, 11, 1-16.	0.0	0
250	Quimioterapia y terapias dirigidas en el tratamiento de los c�nceres de las v�as aerodigestivas superiores (excluido el linfoma maligno). EMC - Otorrinolaringolog�a, 2012, 41, 1-18.	0.0	0
251	Alterations of Phosphoproteins in NCI-H526 Small Cell Lung Cancer Cells Involved in Cytotoxicity of Cisplatin and Titanocene Y. Neoplasia, 2012, 14, 813-822.	2.3	19
252	Photoinduced Ligand Exchange and Covalent DNA Binding by Two New Dirhodium Bis-Amidato Complexes. Inorganic Chemistry, 2012, 51, 11882-11890.	1.9	22
253	Therapeutic Drug Monitoring in Interstitial Fluid: A Feasibility Study Using a Comprehensive Panel of Drugs. Journal of Pharmaceutical Sciences, 2012, 101, 4642-4652.	1.6	35
254	Acupuncture and Moxibustion for Side Effects of Chemotherapy in Cancer Patients. Evidence-based Anticancer Complementary and Alternative Medicine, 2012, , 153-181.	0.1	0
255	Oxidative Stress in Cancer Biology and Therapy. , 2012, , .		5
256	Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin. Dalton Transactions, 2012, 41, 3313.	1.6	38
257	Intracerebral delivery of Carboplatin in combination with either 6 MV Photons or monoenergetic synchrotron X-rays are equally efficacious for treatment of the F98 rat glioma. Journal of Experimental and Clinical Cancer Research, 2012, 31, 78.	3.5	17
258	Cisplatin-loaded core cross-linked micelles: comparative pharmacokinetics, antitumor activity, and toxicity in mice. International Journal of Nanomedicine, 2012, 7, 2557.	3.3	51
259	Hypotension due to Chemotherapy in a Patient with Small Cell Lung Cancer and Lambert-Eaton Myasthenic Syndrome Undergoing Hemodialysis: A First Case Report. Case Reports in Oncology, 2012, 5, 52-55.	0.3	1
261	Antioxidants and Inhibition of Cisplatin-Induced Kidney Injury: Role of Mitochondria. , 2012, , 407-425.		2
262	Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 845-848.	1.1	19
263	Glutathione modified <sc>CdTe</sc> quantum dots as a label for studying <sc>DNA</sc> interactions with platinum based cytostatics. Electrophoresis, 2013, 34, 801-808.	1.3	9
264	Taurine 8. Advances in Experimental Medicine and Biology, 2013, , .	0.8	1
265	Carbon nanotubes for delivery of small molecule drugs. Advanced Drug Delivery Reviews, 2013, 65, 1964-2015.	6.6	498

#	ARTICLE	IF	CITATIONS
266	Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1033-1039.	1.1	17
267	Lipid-Coated Cisplatin Nanoparticles Induce Neighboring Effect and Exhibit Enhanced Anticancer Efficacy. <i>ACS Nano</i> , 2013, 7, 9896-9904.	7.3	125
268	Nanocarriers for delivery of platinum anticancer drugs. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1667-1685.	6.6	345
269	Fucoxanthin Enhances Cisplatin-Induced Cytotoxicity via NF $\kappa$ B-Mediated Pathway and Downregulates DNA Repair Gene Expression in Human Hepatoma HepG2 Cells. <i>Marine Drugs</i> , 2013, 11, 50-66.	2.2	55
270	Kinetics and mechanism of interaction of some bioactive ligands with cis-diaqua(cis-1,2-diaminocyclohexane)platinum(II) in aqueous medium. <i>Journal of Chemical Sciences</i> , 2013, 125, 1133-1143.	0.7	2
271	Copper(II) complexes with substituted imidazole and chlorido ligands: X-ray, UV-Vis, magnetic and EPR studies and chemotherapeutic potential. <i>Polyhedron</i> , 2013, 65, 288-297.	1.0	43
272	Conjunctive Therapy of Cisplatin With the OCT2 Inhibitor Cimetidine: Influence on Antitumor Efficacy and Systemic Clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 94, 585-592.	2.3	72
273	Principles of Cytotoxic Chemotherapy. , 2013, , 167-185.		0
274	Antineoplastic drug, carboplatin, protects mice against visceral leishmaniasis. <i>Parasitology Research</i> , 2013, 112, 91-100.	0.6	14
275	N-Acetyl-L-cysteine modulates the metabolism of cis-platin in human plasma in vitro. <i>Metallomics</i> , 2013, 5, 197.	1.0	19
276	A New Nanotechnology Technique for Determining Drug Efficacy Using Targeted Plasmonically Enhanced Single Cell Imaging Spectroscopy. <i>Journal of the American Chemical Society</i> , 2013, 135, 4688-4691.	6.6	70
277	A Biocompatible <i>in Vivo</i> Ligation Reaction and Its Application for Noninvasive Bioluminescent Imaging of Protease Activity in Living Mice. <i>ACS Chemical Biology</i> , 2013, 8, 987-999.	1.6	51
278	Understanding the preferential binding interaction of aqua-cisplatin with nucleobase guanine over adenine: a density functional reactivity theory based approach. <i>RSC Advances</i> , 2013, 3, 2822.	1.7	32
279	Chemotherapy in Patients with Anthracycline and Taxane-Pretreated Metastatic Breast Cancer: An Overview. <i>Current Breast Cancer Reports</i> , 2013, 5, 42-50.	0.5	52
280	Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer. <i>Journal of Controlled Release</i> , 2013, 171, 339-348.	4.8	98
281	Hydrated Electrons React with High Specificity with Cisplatin Bound to Single-Stranded DNA. <i>Journal of Physical Chemistry B</i> , 2013, 117, 15994-15999.	1.2	11
282	Isomerization of Platinum-Coordinated Iminoethers Induced by Spectator Ligands: Stabilization of the Zanti Configuration. <i>Inorganic Chemistry</i> , 2013, 52, 13058-13067.	1.9	3
283	Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models. <i>Journal of Ovarian Research</i> , 2013, 6, 78.	1.3	17



#	ARTICLE	IF	CITATIONS
284	Assessment of Vandetanib as an Inhibitor of Various Human Renal Transporters: Inhibition of Multidrug and Toxin Extrusion as a Possible Mechanism Leading to Decreased Cisplatin and Creatinine Clearance. <i>Drug Metabolism and Disposition</i> , 2013, 41, 2095-2103.	1.7	49
285	Combined chemotherapy with gemcitabine and carboplatin for metastatic urothelial carcinomas in patients with high renal insufficiency. <i>International Journal of Clinical Oncology</i> , 2013, 18, 910-915.	1.0	3
286	Cisplatin and dietary ascorbic acid mediated changes in the mitochondria of Dalton's lymphoma-bearing mice. <i>Fundamental and Clinical Pharmacology</i> , 2013, 27, 329-338.	1.0	6
287	THEORETICAL STUDY ON THE BINDING OF THE ANTICANCER DRUGS Cis/Trans-[PtCl <sub>2</sub> (NH <sub>3</sub> ){HN = C(CH <sub>3</sub> ) <sub>2</sub> }] AND Cis/Trans-[PtCl <sub>2</sub> {HN = C(CH <sub>3</sub> ) <sub>2</sub> } <sub>2</sub> ] TO PURINE BASES. <i>Journal of Theoretical and Computational Chemistry</i> , 2013, 12, 1350020.	1.8	1
288	A Phase I Study of Concurrent Weekly Carboplatin and Paclitaxel Combined With Intensity-Modulated Pelvic Radiotherapy as an Adjuvant Treatment for Early-Stage Cervical Cancer Patients With Positive Pelvic Lymph Nodes. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1279-1286.	1.2	12
289	Platinum compounds in children with cancer. <i>Anti-Cancer Drugs</i> , 2013, 24, 1007-1019.	0.7	108
290	A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. <i>Cancer Medicine</i> , 2013, 2, 86-98.	1.3	19
291	Radiation with cisplatin or carboplatin for locally advanced cervix cancer: The experience of a tertiary cancer centre. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2013, 57, 97-104.	0.9	11
292	Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 498-503.	0.7	16
293	Cisplatin for small cell lung cancer: Associated publications in Science Citation Index Expanded. <i>Oncology Letters</i> , 2013, 5, 684-688.	0.8	5
294	Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation. <i>Oncology Reports</i> , 2013, 29, 1285-1292.	1.2	173
295	Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2013, 5, 37.	1.0	2
296	Target-directed catalytic metallodrugs. <i>Brazilian Journal of Medical and Biological Research</i> , 2013, 46, 465-485.	0.7	24
297	Role of the DNA Base Excision Repair Protein, APE1 in Cisplatin, Oxaliplatin, or Carboplatin Induced Sensory Neuropathy. <i>PLoS ONE</i> , 2014, 9, e106485.	1.1	88
298	Comparison of Short and Continuous Hydration Regimen in Chemotherapy Containing Intermediate- to High-Dose Cisplatin. <i>Journal of Oncology</i> , 2014, 2014, 1-4.	0.6	16
299	DISEÑO DE FÁRMACOS ANTICANCEROSOS DERIVADOS DE CIS-PLATINO(II) MEDIANTE LA TÉCNICA QSAR, BASADA EN EL FUNCIONAL DE LA DENSIDAD. <i>Informacion Tecnológica (discontinued)</i> , 2014, 25, 161-172.	0.1	2
300	Review of cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments. <i>Oncology Reviews</i> , 2014, 8, 256.	0.8	65
301	Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro. <i>Tumor Biology</i> , 2014, 35, 10879-10890.	0.8	9

#	ARTICLE	IF	CITATIONS
302	Antitumor activity of [Pt(O, Oâ€™-acac)(Î³-acac)(DMS)] in mouse xenograft model of breast cancer. Cell Death and Disease, 2014, 5, e1014-e1014.	2.7	17
303	Effects of SC-560 in Combination with Cisplatin or Taxol on Angiogenesis in Human Ovarian Cancer Xenografts. International Journal of Molecular Sciences, 2014, 15, 19265-19280.	1.8	9
304	Genotoxic Anti-Cancer Agents and Their Relationship to DNA Damage, Mitosis, and Checkpoint Adaptation in Proliferating Cancer Cells. International Journal of Molecular Sciences, 2014, 15, 3403-3431.	1.8	155
305	Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin. Cancers, 2014, 6, 1487-1499.	1.7	5
306	Biomarkers to assess the efficiency of treatment with platinum-based drugs: what can metallomics add?. Metallomics, 2014, 6, 2176-2188.	1.0	1
307	Synthesis and <i>in vitro</i> activity of platinum containing 2-oxazoline-based glycopolymers. Journal of Polymer Science Part A, 2014, 52, 2703-2714.	2.5	12
308	Protein Binding. Cancer Drug Discovery and Development, 2014, , 209-227.	0.2	0
309	Rational Combination Therapy of Vintafolide (EC145) with Commonly Used Chemotherapeutic Drugs. Clinical Cancer Research, 2014, 20, 2104-2114.	3.2	24
310	Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer. Molecular and Clinical Oncology, 2014, 2, 405-410.	0.4	5
311	Oxaliplatin Hypersensitivity: Evaluation, Implications of Skin Testing, and Desensitization. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 40-45.	2.0	65
312	Local chemotherapeutic agents for the treatment of ocular malignancies. Survey of Ophthalmology, 2014, 59, 97-114.	1.7	23
313	Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. Investigational New Drugs, 2014, 32, 154-159.	1.2	8
314	Simultaneous observation of the metabolism of cisplatin and NAMI-A in human plasma <i>in vitro</i> by SEC-ICP-AES. Journal of Biological Inorganic Chemistry, 2014, 19, 1049-1053.	1.1	12
315	A Population Pharmacodynamic Model for Lactate Dehydrogenase and Neuron Specific Enolase to Predict Tumor Progression in Small Cell Lung Cancer Patients. AAPS Journal, 2014, 16, 609-619.	2.2	26
316	Cisplatin Loaded Methoxy Poly (ethylene glycol)- <i>block</i> -Poly (<sc>L</sc> -glutamic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 187 T Macromolecular Bioscience, 2014, 14, 1337-1345.	2.1	34
317	Expression of Stress-Dependent Genes in Hepatocytes Spheroids after Cisplatin Treatment. Bulletin of Experimental Biology and Medicine, 2014, 157, 603-607.	0.3	2
318	Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902. Cancer Chemotherapy and Pharmacology, 2014, 74, 1149-1157.	1.1	11
319	Chemoprotection by<sc>d</sc>-methionine against cisplatin-induced side-effects: insight from <i>in vitro</i> studies using human plasma. Metallomics, 2014, 6, 532-541.	1.0	22

#	ARTICLE	IF	CITATIONS
320	Enzyme-triggered supramolecular self-assembly of platinum prodrug with enhanced tumor-selective accumulation and reduced systemic toxicity. <i>Journal of Materials Chemistry B</i> , 2014, 2, 8303-8309.	2.9	40
321	A density functional reactivity theory (DFRT) based approach to understand the interaction of cisplatin analogues with protecting agents. <i>Journal of Computer-Aided Molecular Design</i> , 2014, 28, 1153-1173.	1.3	11
322	Marked Improvement in Photoinduced Cell Death by a New Tris-heteroleptic Complex with Dual Action: Singlet Oxygen Sensitization and Ligand Dissociation. <i>Journal of the American Chemical Society</i> , 2014, 136, 17095-17101.	6.6	169
323	NanoSIMS combined with fluorescence microscopy as a tool for subcellular imaging of isotopically labeled platinum-based anticancer drugs. <i>Chemical Science</i> , 2014, 5, 3135-3143.	3.7	87
324	Role of Autophagy in Cisplatin Resistance in Ovarian Cancer Cells. <i>Journal of Biological Chemistry</i> , 2014, 289, 17163-17173.	1.6	214
325	Fortification of blood plasma from cancer patients with human serum albumin decreases the concentration of cisplatin-derived toxic hydrolysis products in vitro. <i>Metallomics</i> , 2014, 6, 2034-2041.	1.0	23
326	Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol. <i>Annals of Pharmacotherapy</i> , 2014, 48, 863-869.	0.9	44
327	Longitudinal Serum Testosterone, Luteinizing Hormone, and Follicle-Stimulating Hormone Levels in a Population-Based Sample of Long-Term Testicular Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2014, 32, 571-578.	0.8	84
328	Cisplatin in cancer therapy: Molecular mechanisms of action. <i>European Journal of Pharmacology</i> , 2014, 740, 364-378.	1.7	3,667
329	Lung Cancer in Older Adults. <i>Current Geriatrics Reports</i> , 2014, 3, 166-174.	1.1	0
330	A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 497-502.	1.1	4
331	Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 425-434.	0.8	6
332	Cisplatin Intrastrand Adducts Sensitize DNA to Base Damage by Hydrated Electrons. <i>Journal of Physical Chemistry B</i> , 2014, 118, 4803-4808.	1.2	24
333	Therapeutic Melting Pot of Never in Mitosis Gene A Related Kinase 2 (Nek2): A Perspective on Nek2 as an Oncology Target and Recent Advancements in Nek2 Small Molecule Inhibition. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5835-5844.	2.9	21
334	Encapsulation in Nanoparticles Improves Anti-cancer Efficacy of Carboplatin. <i>AAPS PharmSciTech</i> , 2014, 15, 1029-1038.	1.5	39
335	Sequential extraction of platinum, cisplatin and carboplatin from environmental samples and pre-concentration/separation using vesicular coacervative extraction and determination by continuum source ETAAS. <i>Talanta</i> , 2014, 118, 37-44.	2.9	11
336	Malignant melanoma of the third eyelid in a horse. <i>Equine Veterinary Education</i> , 2015, 27, e15.	0.3	14
337	Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer. <i>Biological and Pharmaceutical Bulletin</i> , 2015, 38, 1192-1198.	0.6	18

#	ARTICLE	IF	CITATIONS
338	Pharmacokinetics of Carboplatin in a One-Year-Old Anuric Boy Undergoing Hemodialysis and a Review of the Literature. <i>Therapeutic Apheresis and Dialysis</i> , 2015, 19, 491-496.	0.4	3
339	Case Report of a Patient with Left Ventricular Assistance Device Undergoing Chemotherapy for a New Diagnosis of Lung Cancer. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-3.	0.2	4
340	Outcomes of Small Cell Lung Cancer Patients Treated With Cisplatin-Etoposide Versus Carboplatin-Etoposide. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 51-54.	0.6	27
341	Lung cancer chemotherapy agents increase procoagulant activity via protein disulfide isomerase-dependent tissue factor decryption. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 36-45.	0.5	25
342	Early measurement of urinary N-acetyl-β-D-glucosaminidase helps predict severe hyponatremia associated with cisplatin-containing chemotherapy. <i>Journal of Infection and Chemotherapy</i> , 2015, 21, 502-506.	0.8	7
343	Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells. <i>International Journal of Oncology</i> , 2015, 47, 353-360.	1.4	34
344	A theranostic prodrug delivery system based on Pt(IV) conjugated nano-graphene oxide with synergistic effect to enhance the therapeutic efficacy of Pt drug. <i>Biomaterials</i> , 2015, 51, 12-21.	5.7	109
345	Carboplatin and weekly paclitaxel chemotherapy in hemodialysis patient with advanced lung cancer and severe comorbidity: effect of the drugs and their chemical intermediates. <i>Research on Chemical Intermediates</i> , 2015, 41, 6825-6832.	1.3	0
346	The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas. <i>Oral Oncology</i> , 2015, 51, 423-430.	0.8	39
347	Radiosensitization of DNA by Cisplatin Adducts Results from an Increase in the Rate Constant for the Reaction with Hydrated Electrons and Formation of Pt <sup>I</sup> . <i>Journal of Physical Chemistry B</i> , 2015, 119, 9496-9500.	1.2	17
348	STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2103-2111.	1.9	19
349	Synthesis, characterization, DNA/BSA interactions and anticancer activity of achiral and chiral copper complexes. <i>Dalton Transactions</i> , 2015, 44, 9516-9527.	1.6	47
350	Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy – the SpheroNEO study. <i>BMC Cancer</i> , 2015, 15, 519.	1.1	26
351	APE1, the DNA base excision repair protein, regulates the removal of platinum adducts in sensory neuronal cultures by NER. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2015, 779, 96-104.	0.4	31
352	Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells. <i>Experimental Cell Research</i> , 2015, 336, 1-14.	1.2	16
353	Improved cisplatin delivery in cervical cancer cells by utilizing folate-grafted non-aggregated gelatin nanoparticles. <i>Biomedicine and Pharmacotherapy</i> , 2015, 69, 1-10.	2.5	69
354	Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells. <i>Biomarker Insights</i> , 2016, 11, BMI.S39445.	1.0	52
355	Antitumor Activity of 2,9-Di-Sec-Butyl-1,10-Phenanthroline. <i>PLoS ONE</i> , 2016, 11, e0168450.	1.1	3

#	ARTICLE	IF	CITATIONS
356	Platinum-containing cytostatic drugs. , 2016, , 810-833.		0
357	Morin Hydrate Mitigates Cisplatin-Induced Renal and Hepatic Injury by Impeding Oxidative/Nitrosative Stress and Inflammation in Mice. <i>Journal of Biochemical and Molecular Toxicology</i> , 2016, 30, 571-579.	1.4	21
358	Impact of Isotope Dilution Mass Spectrometry (IDMS) Standardization on Carboplatin Dose and Adverse Events. <i>Pharmacotherapy</i> , 2016, 36, 617-622.	1.2	6
359	Early Decreases in $\alpha$ -Fetoprotein and Des- $\gamma$ -carboxy Prothrombin Predict the Antitumor Effects of Hepatic Transarterial Infusion Chemotherapy with Cisplatin (CDDP) Powder in Patients with Advanced Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2016, 55, 2163-2171.	0.3	3
360	Role of Wnt/ $\beta$ -catenin, Wnt/c-Jun N-terminal kinase and Wnt/Ca <sup>2+</sup> pathways in cisplatin-induced chemoresistance in ovarian cancer. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 3851-3858.	0.8	29
361	Pemetrexed-Induced Nephrogenic Diabetes Insipidus. <i>American Journal of Kidney Diseases</i> , 2016, 68, 628-632.	2.1	6
362	Ni( $\text{Ni}(\text{Ni})$ )/Cu( $\text{Cu}(\text{Cu})$ )/Zn( $\text{Zn}(\text{Zn})$ ) 5,5-diethylbarbiturate complexes with 1,10-phenanthroline and 2,2'-dipyridylamine: synthesis, structures, DNA/BSA binding, nuclease activity, molecular docking, cellular uptake, cytotoxicity and the mode of cell death. <i>Dalton Transactions</i> , 2016, 45, 10466-10479.	1.6	37
363	Antitumor effect of arabinogalactan and platinum complex. <i>Doklady Biochemistry and Biophysics</i> , 2016, 467, 92-94.	0.3	3
364	Efficacy and mucosal toxicity of concomitant chemo-radiotherapy in patients with locally-advanced squamous cell carcinoma of the head-and-neck in the light of a novel mathematical model. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 101-110.	2.0	10
365	Water-soluble and photo-stable silver(I) dicarboxylate complexes containing 1,10-phenanthroline ligands: Antimicrobial and anticancer chemotherapeutic potential, DNA interactions and antioxidant activity. <i>Journal of Inorganic Biochemistry</i> , 2016, 159, 120-132.	1.5	52
366	Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand. <i>BMC Cancer</i> , 2016, 16, 501.	1.1	15
367	VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells. <i>Molecular Pharmaceutics</i> , 2016, 13, 3712-3723.	2.3	47
368	Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1543-1549.	1.7	26
369	Modulation of the metabolism of <i>cis</i> -platin in blood plasma by glutathione. <i>Canadian Journal of Chemistry</i> , 2016, 94, 360-366.	0.6	8
370	An asymmetric binuclear zinc( $\text{Zn}(\text{Zn})$ ) complex with mixed iminodiacetate and phenanthroline ligands: synthesis, characterization, structural conversion and anticancer properties. <i>Inorganic Chemistry Frontiers</i> , 2016, 3, 959-968.	3.0	24
371	Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis. <i>Pharmacogenomics</i> , 2016, 17, 1089-1112.	0.6	12
372	Intratracheal Administration of Hyaluronan-Cisplatin Conjugate Nanoparticles Significantly Attenuates Lung Cancer Growth in Mice. <i>Pharmaceutical Research</i> , 2016, 33, 2517-2529.	1.7	32
373	Kiteplatin: Differential binding between GSH and GMP. <i>Inorganica Chimica Acta</i> , 2016, 452, 130-136.	1.2	3

#	ARTICLE	IF	CITATIONS
374	Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 1891-1900.	1.6	7
375	Metal-based drugs that break the rules. <i>Dalton Transactions</i> , 2016, 45, 3201-3209.	1.6	258
376	The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 19-26.	1.1	37
377	Craniospinal irradiation with concomitant and adjuvant temozolomide—a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. <i>Journal of Neuro-Oncology</i> , 2016, 127, 295-302.	1.4	8
378	Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study. <i>Lung Cancer</i> , 2016, 92, 35-40.	0.9	15
379	Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 31-36.	0.5	16
380	Binding interactions of mixed ligand copper(II) amino acid Schiff base complexes with biological targets: Spectroscopic evaluation and molecular docking. <i>Applied Organometallic Chemistry</i> , 2017, 31, e3713.	1.7	35
381	Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck. <i>Laryngoscope</i> , 2017, 127, 2260-2264.	1.1	6
382	X-ray Structure of the Carboplatin-Loaded Apo-Ferritin Nanocage. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 433-437.	1.3	21
383	Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors. <i>Oncologist</i> , 2017, 22, 222-235.	1.9	25
384	Does lymphadenectomy have influence on postoperative body fluid distribution?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 212, 182-185.	0.5	1
385	Near-infrared light stimuli-responsive synergistic therapy nanoplatforms based on the coordination of tellurium-containing block polymer and cisplatin for cancer treatment. <i>Biomaterials</i> , 2017, 133, 208-218.	5.7	124
386	The impact of a solitary kidney on tolerability to gemcitabine plus cisplatin chemotherapy in urothelial carcinoma patients: a retrospective study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 995-1001.	1.1	0
387	A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. <i>Oncologist</i> , 2017, 22, 609-619.	1.9	253
388	Carboplatin-Complexed and cRGD-Conjugated Unimolecular Nanoparticles for Targeted Ovarian Cancer Therapy. <i>Macromolecular Bioscience</i> , 2017, 17, 1600292.	2.1	28
389	Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 223-233.	1.1	60
390	Formation of platinum (II) as a six member ring for sustained polymeric delivery. <i>European Journal of Medicinal Chemistry</i> , 2017, 136, 452-456.	2.6	2
391	Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 347-358.	1.3	27

#	ARTICLE	IF	CITATIONS
392	Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. <i>Oral Oncology</i> , 2017, 71, 26-33.	0.8	172
393	Magnesium attenuates cisplatin-induced nephrotoxicity by regulating the expression of renal transporters. <i>European Journal of Pharmacology</i> , 2017, 811, 191-198.	1.7	37
394	Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 943-949.	1.1	38
395	Quantification and clinical application of carboplatin in plasma ultrafiltrate. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 138, 373-377.	1.4	7
396	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy. <i>Neuroendocrinology</i> , 2017, 105, 281-294.	1.2	94
397	Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis. <i>Supportive Care in Cancer</i> , 2017, 25, 1215-1220.	1.0	15
398	Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration. <i>Life Sciences</i> , 2017, 189, 18-22.	2.0	19
399	Pregabalin reduces cisplatin-induced mechanical allodynia in rats. <i>Journal of Pharmacological Sciences</i> , 2017, 134, 175-180.	1.1	14
400	Developing better mouse models to study cisplatin-induced kidney injury. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, F835-F841.	1.3	85
401	Alternative Chemotherapeutic Agents for the Treatment of Retinoblastoma Using the Intra-Arterial and Intravitreal Routes: A Path Forward Toward Drug Discovery. <i>International Ophthalmology Clinics</i> , 2017, 57, 129-141.	0.3	10
402	Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. <i>European Journal of Cancer</i> , 2017, 83, 302-312.	1.3	18
403	Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma. <i>Cancer Immunology Research</i> , 2017, 5, 1141-1151.	1.6	160
404	Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. <i>Supportive Care in Cancer</i> , 2017, 25, 481-487.	1.0	35
405	Outcomes of nonsurgical management of locally advanced carcinomas of the sinonasal cavity. <i>Laryngoscope</i> , 2017, 127, 855-861.	1.1	31
406	Effect of HPV E6/E7 siRNA with Chemotherapeutic Agents on the Regulation of TP53/E2F Dynamic Behavior for Cell Fate Decisions. <i>Neoplasia</i> , 2017, 19, 735-749.	2.3	14
407	Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy. <i>Frontiers in Pharmacology</i> , 2017, 8, 911.	1.6	55
408	Treatment of esophageal cancer with radiation therapy: a pan-Chinese survey of radiation oncologists. <i>Oncotarget</i> , 2017, 8, 34946-34953.	0.8	6
410	7. MEDICINAL CHEMISTRY OF GOLD ANTICANCER METALLODRUGS. , 2018, 18, 199-218.		82

#	ARTICLE	IF	CITATIONS
411	Combining chemotherapy with PD-1 blockade in NSCLC. , 2018, 186, 130-137.		97
412	Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). <i>Annals of Oncology</i> , 2018, 29, 1004-1009.	0.6	68
413	Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer. <i>Advances in Cancer Research</i> , 2018, 137, 37-75.	1.9	153
414	Hyaluronic acid-coated cisplatin conjugated gold nanoparticles for combined cancer treatment. <i>Journal of Industrial and Engineering Chemistry</i> , 2018, 65, 236-243.	2.9	35
415	Effect of lipophilicity of amylamine and amylglycine ligands on biological activity of new anticancer cisplatin analog. <i>Journal of Biomolecular Structure and Dynamics</i> , 2018, 36, 893-905.	2.0	17
416	A new class of platinum( <sup>II</sup> ) complexes with the phosphine ligand pta which show potent anticancer activity. <i>Inorganic Chemistry Frontiers</i> , 2018, 5, 39-53.	3.0	44
417	Cisplatin-induced human peripheral blood mononuclear cells's oxidative stress and nephrotoxicity in head and neck cancer patients: the influence of hydrogen peroxide. <i>Molecular and Cellular Biochemistry</i> , 2018, 440, 139-145.	1.4	12
418	An approach for quantification of platinum distribution in tissues by LA-ICP-MS imaging using isotope dilution analysis. <i>Talanta</i> , 2018, 178, 166-171.	2.9	32
419	Syntheses of Zn(II) and Cu(II) Schiff base complexes using N,O donor Schiff base ligand: Crystal structure, DNA binding, DNA cleavage, docking and DFT study. <i>Polyhedron</i> , 2018, 141, 153-163.	1.0	55
420	Two cases of combination therapy with cetuximab, paclitaxel, and cisplatin for advanced head and neck cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 553-554.	0.5	5
421	Chemoradiotherapy completion and neutropenia risk in HIV patients with cervical cancer. <i>Medicine (United States)</i> , 2018, 97, e11592.	0.4	8
422	Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients. <i>Lung Cancer</i> , 2018, 126, 156-161.	0.9	3
423	Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. <i>Cancers</i> , 2018, 10, 506.	1.7	40
424	Analysis of the Interaction Between the C20 Cage and cis-PtCl <sub>2</sub> (NH <sub>3</sub> ) <sub>2</sub> : A DFT Investigation of the Solvent Effect, Structures, Properties, and Topologies. <i>Journal of Structural Chemistry</i> , 2018, 59, 1044-1051.	0.3	7
425	Carboplatin's Angelica gigas Nakai combination synergistically enhances apoptosis by suppressed Akt, Erk, and Stat3 expression in H460 human lung cancer cells. <i>European Journal of Inflammation</i> , 2018, 16, 205873921880534.	0.2	1
426	Comparing outcomes of concurrent chemotherapy regimens in patients 65 years old or older with locally advanced oropharyngeal carcinoma. <i>Cancer</i> , 2018, 124, 4322-4331.	2.0	8
427	Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer. <i>JAMA Neurology</i> , 2018, 75, 980.	4.5	73
428	IDH1's mutant cancer cells are sensitive to cisplatin and an IDH1's mutant inhibitor counteracts this sensitivity. <i>FASEB Journal</i> , 2018, 32, 6344-6352.	0.2	28



#	ARTICLE	IF	CITATIONS
429	Carboplatin as an alternative to Cisplatin in chemotherapies: New insights at single molecule level. <i>Biophysical Chemistry</i> , 2018, 241, 8-14.	1.5	15
430	Inhibition of Intracellular ROS Accumulation by Formononetin Attenuates Cisplatin-Mediated Apoptosis in LLC-PK1 Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 813.	1.8	24
431	Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 1118-1130.	1.8	13
432	Tumor necrosis factor $\alpha$ -induced protein 8 expression as a predictor of prognosis and resistance in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy. <i>Human Pathology</i> , 2018, 82, 239-248.	1.1	8
433	The Genesis of the Neuroendocrine Tumors Concept. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 711-731.	1.2	17
434	Synthesis, <i>in vitro</i> cytotoxicity, and structure-activity relationships (SAR) of multidentate oxidovanadium(IV) complexes as anticancer agents. <i>Dalton Transactions</i> , 2018, 47, 10035-10045.	1.6	38
435	An Antitumor Bis(N-heterocyclic Carbene)Platinum(II) Complex That Engages Asparagine Synthetase as an Anticancer Target. <i>Angewandte Chemie</i> , 2019, 131, 11030-11034.	1.6	42
436	Carboplatin Enhances the Activity of Human Transient Receptor Potential Ankyrin 1 through the Cyclic AMP-Protein Kinase A-Kinase Anchoring Protein (AKAP) Pathways. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3271.	1.8	14
437	Recent advances in ruthenium and platinum based supramolecular coordination complexes for antitumor therapy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2019, 182, 110373.	2.5	21
438	Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. <i>Oral Oncology</i> , 2019, 95, 127-135.	0.8	103
439	Remote Ischemic Preconditioning Protects Cisplatin-Induced Acute Kidney Injury through the PTEN/AKT Signaling Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-10.	1.9	13
440	Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 1049-1054.	0.6	14
441	Cisplatin or carboplatin? Neutrophil to lymphocyte ratio may serve as a useful factor in small cell lung cancer therapy selection. <i>Oncology Letters</i> , 2019, 18, 1513-1520.	0.8	6
442	A glycine spacer improved peptidyl-nuclear-localized efficiency for fluorescent imaging nuclear H <sub>2</sub> O <sub>2</sub> . <i>Sensors and Actuators B: Chemical</i> , 2019, 296, 126624.	4.0	15
443	An Antitumor Bis(N-heterocyclic Carbene)Platinum(II) Complex That Engages Asparagine Synthetase as an Anticancer Target. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 10914-10918.	7.2	49
444	Theoretical Study of the Interaction between Graphyne and cis-PtCl <sub>2</sub> (NH <sub>3</sub> ) <sub>2</sub> Complex. <i>Russian Journal of Inorganic Chemistry</i> , 2019, 64, 369-376.	0.3	1
445	Cisplatin: The first metal based anticancer drug. <i>Bioorganic Chemistry</i> , 2019, 88, 102925.	2.0	961
446	Accurate quantification of carboplatin adducts with serum proteins by monolithic chromatography coupled to ICPMS with isotope dilution analysis. <i>Journal of Analytical Atomic Spectrometry</i> , 2019, 34, 729-740.	1.6	12

#	ARTICLE	IF	CITATIONS
447	Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment. <i>Clinical Cancer Research</i> , 2019, 25, 7243-7255.	3.2	57
448	Photocytotoxic cancer cell-targeting platinum(II) complexes of glucose-appended curcumin and biotinylated 1,10-phenanthroline. <i>Dalton Transactions</i> , 2019, 48, 17556-17565.	1.6	28
449	Citrus aurantium Ameliorates Cisplatin-Induced Nephrotoxicity. <i>BioMed Research International</i> , 2019, 2019, 1-9.	0.9	12
450	Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for patients with hepatoblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27425.	0.8	4
451	Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors. <i>Carcinogenesis</i> , 2019, 40, 998-1009.	1.3	20
452	The anticancer effects and mechanisms of fucoxanthin combined with other drugs. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 293-301.	1.2	20
453	Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities. <i>Clinical Cancer Research</i> , 2019, 25, 1147-1155.	3.2	72
454	Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 136-146.	1.1	10
455	Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 44-51.	0.5	10
456	Correlation between mouse age and human age in anti-tumor research: Significance and method establishment. <i>Life Sciences</i> , 2020, 242, 117242.	2.0	98
457	Chemotherapy in chronic kidney disease and dialysis. , 2020, , 183-196.e7.		0
458	One-Pot Synthesis of New Organometallic Compounds with Platinum-Carbon Bond. <i>European Journal of Inorganic Chemistry</i> , 2020, 2020, 1018-1026.	1.0	1
459	Successful treatment of a patient with small cell lung cancer receiving hemodialysis, with concurrent oral etoposide and radiotherapy. <i>Medicine (United States)</i> , 2020, 99, e22637.	0.4	4
460	Andrographolide suppresses cisplatin-induced endothelial hyperpermeability through activation of PI3K/Akt and eNOS-derived nitric oxide. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115809.	1.4	5
461	Comparative Study of the Mode of Action of Clinically Approved Platinum-Based Chemotherapeutics. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6928.	1.8	40
462	Review of comparative studies of cytotoxic activities of Pt(II), Pd(II), Ru(II)/(III) and Au(III) complexes, their kinetics of ligand substitution reactions and DNA/BSA interactions. <i>Inorganica Chimica Acta</i> , 2020, 512, 119883.	1.2	46
463	Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation. <i>AAPS Journal</i> , 2020, 22, 143.	2.2	5
464	The Role of Adjuvant Treatment in Craniofacial Malignancy: A Critical Review. <i>Frontiers in Oncology</i> , 2020, 10, 1402.	1.3	7

#	ARTICLE	IF	CITATIONS
465	PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?. Medicines (Basel, Switzerland), 2020, 7, 54.	0.7	21
466	Hydrated electrons induce the formation of interstrand cross-links in DNA modified by cisplatin adducts. Journal of Radiation Research, 2020, 61, 343-351.	0.8	2
467	Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells. International Journal of Molecular Sciences, 2020, 21, 5788.	1.8	11
468	Facile synthesis of heterobimetallic [FeII(μ-diphosphine)RuII] and homobimetallic [FeII(μ-diphosphine)FeII] complexes and their in vitro cytotoxic activity on cisplatin-resistant cancer cells. Inorganica Chimica Acta, 2020, 510, 119731.	1.2	7
469	Assessment and Management of Platinum-Related Ototoxicity in Children Treated for Cancer. Cancers, 2020, 12, 1266.	1.7	39
470	Synthesis, structure and anti-cancer activity of osmium complexes bearing π-bound arene substituents and phosphane Co-Ligands: A review. European Journal of Medicinal Chemistry, 2020, 201, 112483.	2.6	30
471	Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies. Advances in Medical Sciences, 2020, 65, 265-285.	0.9	29
472	Concomitant lansoprazole ameliorates cisplatin-induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats. Biopharmaceutics and Drug Disposition, 2020, 41, 239-247.	1.1	11
473	Limb ischemic preconditioning ameliorates renal microcirculation through activation of PI3K/Akt/eNOS signaling pathway after acute kidney injury. European Journal of Medical Research, 2020, 25, 10.	0.9	11
474	Reduction of the Cisplatin Toxicity by Its Conjugation with Arabinogalactan. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2020, 14, 61-66.	0.3	1
475	The Thioredoxin System: A Promising Target for Cancer Drug Development. Chemistry - A European Journal, 2020, 26, 10175-10184.	1.7	56
476	Oxamusplatin: a cytotoxic Pt(II) complex of a nitrogen mustard with resistance to thiol based sequestration displays enhanced selectivity towards cancer. Dalton Transactions, 2020, 49, 2547-2558.	1.6	13
477	Comparative gonadotoxicity of the chemotherapy drugs cisplatin and carboplatin on prepubertal mouse gonads. Molecular Human Reproduction, 2020, 26, 129-140.	1.3	32
478	Role of SLC transporters in toxicity induced by anticancer drugs. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 493-506.	1.5	15
479	Quantification of cytostatic platinum compounds in wastewater by inductively coupled plasma mass spectrometry after ion exchange extraction. Microchemical Journal, 2020, 157, 104862.	2.3	14
480	ESI MS studies highlight the selective interaction of Auranofin with protein free thiols. Dalton Transactions, 2020, 49, 5906-5913.	1.6	57
481	Cisplatin-induced nephrotoxicity in children: what is the best protective strategy?. Journal of Oncology Pharmacy Practice, 2021, 27, 180-186.	0.5	14
482	New Approved First-line Combining Therapy of NSCLC in 2020. E3S Web of Conferences, 2021, 245, 03057.	0.2	0

#	ARTICLE	IF	CITATIONS
483	nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 485587.	1.3	4
484	The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry. <i>Pharmaceuticals</i> , 2021, 14, 104.	1.7	26
485	The safety of current pharmacotherapeutic strategies for osteosarcoma. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 427-438.	1.0	11
486	mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9. <i>BioMed Research International</i> , 2021, 2021, 1-11.	0.9	11
487	Interaction between carboplatin with B12P12 and Al12P12 nano-clusters: A computational investigation. <i>Phosphorus, Sulfur and Silicon and the Related Elements</i> , 2021, 196, 751-759.	0.8	10
488	Osmium Arene Germyl, Stannyl, Germanate, and Stannate Complexes as Anticancer Agents. <i>ACS Omega</i> , 2021, 6, 19252-19268.	1.6	5
489	Comparative cytotoxic activity of carboplatin and Î <sup>2</sup> -cryptoxanthin in free and liposomal forms against breast cancer cell line. <i>Ukrainian Biochemical Journal</i> , 2021, 93, 49-60.	0.1	2
490	Lipid, polymeric, inorganic-based drug delivery applications for platinum-based anticancer drugs. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120788.	2.6	20
491	Necrostatins regulate apoptosis, necroptosis, and inflammation in cisplatin-induced nephrotoxicity in LLC-PK1 cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 48, 128256.	1.0	0
492	Mesoporous silica nanoparticles functionalized with folic acid for targeted release Cis-Pt to glioblastoma cells. <i>Reviews on Advanced Materials Science</i> , 2021, 60, 25-37.	1.4	21
493	A randomized, phase 1, placebo-controlled trial of APCâ€157 in oral cancer demonstrates systemic absorption and an inhibitory effect on cytokines and tumor-associated microbes. <i>Cancer</i> , 2020, 126, 1668-1682.	2.0	33
494	Taurine Enhances Anticancer Activity of Cisplatin in Human Cervical Cancer Cells. <i>Advances in Experimental Medicine and Biology</i> , 2013, 776, 189-198.	0.8	21
495	Protein Binding of Anticancer Drugs. , 2004, , 169-188.		3
496	Acupuncture and Moxibustion as an Evidence-based Therapy for Cancer. <i>Evidence-based Anticancer Complementary and Alternative Medicine</i> , 2012, , .	0.1	11
497	DNA-binding agents. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003, 21, 171-209.	0.5	5
498	DNA-binding agents. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, , 163-203.	0.5	5
499	Synthesis and redetermination of the crystal structure of salicylaldehyde N<i>(4)</i>-morpholiniothiosemicarbazone. <i>Acta Crystallographica Section E: Crystallographic Communications</i> , 2019, 75, 1389-1393.	0.2	6
501	Cytotoxic Therapy and Other Nonhormonal Approaches for the Treatment of Metastatic Breast Cancer. , 2002, , 417-472.		1

#	ARTICLE	IF	CITATIONS
502	Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin. Biomedical and Pharmacology Journal, 2019, 12, 07-15.	0.2	189
503	Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions. PLoS ONE, 2013, 8, e81162.	1.1	575
504	Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibodies Perspective. World Journal of Oncology, 2014, 5, 97-108.	0.6	15
505	Preclinical Assessment of Low Doses of Cisplatin in the Management of Acute Promyelocytic Leukemia. International Journal of Cancer Research and Molecular Mechanisms, 2015, 1, .	0.2	8
506	Synergistic Effect of Î±-Solanine and Cisplatin Induces Apoptosis and Enhances Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells. Anti-Cancer Agents in Medicinal Chemistry, 2020, 19, 2197-2210.	0.9	17
507	Responses and adverse effects of carboplatin-based chemotherapy for pediatric intracranial germ cell tumors. Korean Journal of Pediatrics, 2011, 54, 128.	1.9	4
508	Gemcitabine and Carboplatin Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Feasibility Study. Cancer Research and Treatment, 2008, 40, 116.	1.3	10
509	Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer. Cancer Research and Treatment, 2015, 47, 687-696.	1.3	11
510	Future perspectives on the treatment of hepatocellular carcinoma with cisplatin. World Journal of Hepatology, 2009, 1, 8.	0.8	34
511	Investigation of Serum Creatinine Rise in Patients after Cisplatin Therapy. Iryo Yakugaku (Japanese) Tj ETQq1 1 0.784314 rgBJ /Overlo	0.0	1
512	MicroRNA in lung cancer. World Journal of Methodology, 2014, 4, 59.	1.1	56
513	Efficacy of Antioxidant Supplements on Prevention and Amelioration of Cisplatin-Induced Nephrotoxicity: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Jundishapur Journal of Natural Pharmaceutical Products, 2019, 14, .	0.3	2
514	The Molecular Basis and Therapeutic Aspects of Cisplatin Resistance in Oral Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 761379.	1.3	38
515	Cisplatin induces lung cell cilia disruption and lung damage via oxidative stress. Free Radical Biology and Medicine, 2021, 177, 270-277.	1.3	16
517	Carboplatin Has Equivalent Efficacy to Cisplatin in the Treatment of Advanced Non-small-cell Lung Cancer?. Japanese Journal of Lung Cancer, 2002, 42, 796-801.	0.0	0
518	Cytotoxic Therapy and Other Nonhormonal Approaches for the Treatment of Metastatic Breast Cancer. , 2002, , 439-494.		0
519	Chemotherapy of Ovarian Cancer. , 2003, , 487-503.		0
521	Chemotherapy for Ovarian Cancer. , 2010, , 143-161.		0

#	ARTICLE	IF	CITATIONS
522	DNA Biosensor for Environmental Risk Assessment and Drugs Studies. , 2010, , 249-276.		0
524	Responses and adverse effects of carboplatin-based chemotherapy for pediatric intracranial germ cell tumors. Korean Journal of Pediatrics, 2011, 54, 127.	1.9	0
526	Systemic Therapies in the Management of Head and Neck Cancer. Head and Neck Cancer Clinics, 2012, , 99-113.	0.0	0
527	Magnesium Salts in a Cancer Patient: Pathobiology and Protective Functions. , 2013, , 159-180.		0
528	Lung Cancer: Diagnosis and Treatment Approach. , 2015, , 97-144.		2
529	Rare Case of Spontaneous Tumor Lysis Syndrome (TLS) in a Patient with Germ Cell Tumor (GCT): Literature Review and Approach to Management. MOJ Clinical & Medical Case Reports, 2017, 7, .	0.0	0
530	Treatment with Cisplatin and Etoposide Chemotherapy in Patient with Metastatic Breast Cancer. Journal of Breast Disease, 2017, 5, 39-45.	0.2	0
531	Small Cell Lung Cancer. , 2019, , 193-210.		0
532	Cisplatin Toxicity in Children with Malignancy. Biomedical and Pharmacology Journal, 2019, 12, 1603-1611.	0.2	4
533	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 5471.	1.7	18
535	Intrapleural treatment in patients with nonâ€small cell lung cancer with malignant pleural effusions in the real world. Thoracic Cancer, 2021, 12, 3416-3425.	0.8	2
536	Future Directions in the Delivery of Hyperthermic Intraperitoneal Chemotherapy. , 2007, , 179-186.		0
538	Antimicrobial activity of mono- and polynuclear platinum and palladium complexes. Foods and Raw Materials, 2020, 8, 298-311.	0.8	13
539	In vitro effects of platinum compounds on renal cellular respiration in mice. International Journal of Clinical and Experimental Pathology, 2015, 8, 81-95.	0.5	0
540	Rapid diagnosis of cisplatin-sensitive and resistant cervical squamous cell carcinomas by reverse transcription loop-mediated isothermal amplification. International Journal of Clinical and Experimental Pathology, 2018, 11, 882-887.	0.5	0
541	Technical modification in the intracarotid chemotherapy and osmotic blood-brain barrier disruption procedure to prevent the relapse of carboplatin-induced orbital pseudotumor. American Journal of Neuroradiology, 2004, 25, 830-4.	1.2	8
542	Carboplatin Dosing in Children Using Estimated Glomerular Filtration Rate: Equation Matters. Cancers, 2021, 13, 5963.	1.7	3
543	The Effect of Chemotherapy on the Ovary Clinical and Pathophysiological Review. , 2022, , 15-34.		0

#	ARTICLE	IF	CITATIONS
544	Kidney-Targeted Redox Scavenger Therapy Prevents Cisplatin-Induced Acute Kidney Injury. <i>Frontiers in Pharmacology</i> , 2021, 12, 790913.	1.6	13
545	Boric acid improves the behavioral, electrophysiological and histological parameters of cisplatin-induced peripheral neuropathy in rats. <i>Journal of Trace Elements in Medicine and Biology</i> , 2022, 70, 126917.	1.5	1
547	Gender and Sex-Related Differences in Normal Tissue Effects Induced by Platinum Compounds. <i>Pharmaceuticals</i> , 2022, 15, 255.	1.7	12
548	Label-Free Target Identification Reveals the Anticancer Mechanism of a Rhenium Isonitrile Complex. <i>Frontiers in Chemistry</i> , 2022, 10, 850638.	1.8	4
549	Conventional Chemotherapy Nephrotoxicity. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 402-414.e1.	0.6	18
550	Self-assembled ruthenium and osmium nanosystems display potent anticancer profile by interfering with metabolic activity. <i>Inorganic Chemistry Frontiers</i> , 0, , .	3.0	1
551	2-Pyrocatechuic Acid Attenuates Carboplatin Induced Hematological Toxicities in Wistar Rats. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 1053-1058.	0.2	1
552	Prognostic Factors for the Therapeutic Performance of Cisplatin in Head and Neck Malignancies. <i>Frontiers in Oncology</i> , 2022, 12, 778380.	1.3	1
553	Suitability of Oral Rehydration Solution (ORS) for Use in the Cisplatin Short Hydration Method. <i>Anticancer Research</i> , 2022, 42, 3185-3193.	0.5	2
554	Genome-Wide Analyses of Nephrotoxicity in Platinum-Treated Cancer Patients Identify Association with Genetic Variant in RBMS3 and Acute Kidney Injury. <i>Journal of Personalized Medicine</i> , 2022, 12, 892.	1.1	2
555	Interaction of organoruthenium(II)-polypyridyl complexes with DNA and BSA. <i>BioMetals</i> , 2022, 35, 813-829.	1.8	1
556	DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?. <i>Cancers</i> , 2022, 14, 2918.	1.7	6
557	Investigation Study of Molecular Modeling for New Pt(IV) Complex Using Density Functional Theory. <i>Arab Gulf Journal of Scientific Research</i> , 2016, , 69-78.	0.3	0
558	Fluorination and hydrolytic stability of water-soluble platinum complexes with a borane-bridged diphosphoramidite ligand. <i>Dalton Transactions</i> , 2022, 51, 12895-12903.	1.6	1
559	Comparative NMR metabolomics of the responses of A2780 human ovarian cancer cells to clinically established Pt-based drugs. <i>Dalton Transactions</i> , 2022, 51, 12512-12523.	1.6	8
560	Gross hematuria secondary to use of carboplatin in neoadjuvant treatment of breast cancer with HER2 overexpression. <i>BMJ Case Reports</i> , 2022, 15, e245407.	0.2	1
561	Exploring the adsorption ability with sensitivity and reactivity of $C_{12}B_6N_6$ , $C_{12}Al_6N_6$ , and $B_6N_6Al_6N_6$ heteronanocages towards the cisplatin drug: a DFT, AIM, and COSMO analysis. <i>RSC Advances</i> , 2022, 12, 29569-29584.	1.7	9
562	Efficacy of Short Hydration for Intermediate to High-Dose Cisplatin-Based Chemotherapy for Outpatients: SHORTCIS Trial. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 3323-3330.	0.5	1

#	ARTICLE	IF	CITATIONS
563	Cisplatin in cancer treatment. <i>Biochemical Pharmacology</i> , 2022, 206, 115323.	2.0	44
564	Nonsurgical Treatment Strategies for Elderly Head and Neck Cancer Patients: An Emerging Subject Worldwide. <i>Cancers</i> , 2022, 14, 5689.	1.7	0
565	Ovarian Reserve Disorders, Can We Prevent Them? A Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15426.	1.8	5
566	Ameliorative impacts of polymeric and metallic nanoparticles on cisplatin-induced nephrotoxicity: a 2011â€“2022 review. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	7
567	Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. <i>Drugs</i> , 2023, 83, 217-248.	4.9	22
568	Intravenous Chemotherapy for Retinoblastoma: A Pediatric Oncologistâ€™s Perspective. , 2022, , 33-43.		0
569	Carbon nanotubes as nanovectors for targeted delivery of platinum based anticancer drugs. , 2023, , 205-227.		0
570	Carbon nanotubes for anticancer therapy: new trends and innovations. , 2023, , 175-204.		0
571	The Wnt/ $\beta$ -catenin signaling pathway plays a role in drug-induced liver injury by regulating cytochrome P450 2E1 expression. <i>Toxicological Research</i> , 2023, 39, 443-453.	1.1	2
572	Imidazolyl Ethanamide Pentandioic Acid (IEPA) as Potential Radical Scavenger during Tumor Therapy in Human Hematopoietic Stem Cells. <i>Molecules</i> , 2023, 28, 2008.	1.7	0
574	Comparison of Renal Functions Evaluated by Measured Glomerular Filtration Rate in Patients Treated With Cisplatin, Carboplatin, and Oxaliplatin. <i>Cureus</i> , 2023, , .	0.2	0
576	Optimal experimental design for efficient toxicity testing in microphysiological systems: A bone marrow application. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
585	Acute Kidney Injury in Oncology. , 2023, , .		0
586	Systemic Onco-sphere: An Overview from the Hostâ€™s Perspective. , 2023, , 391-418.		0